Pub Date : 2025-12-01Epub Date: 2025-04-30DOI: 10.1016/j.jbspin.2025.105917
Michal Carmiel-Haggai , Rula Daood , Fadi Fassan , Helana Jeries , Dikla Dror-Zur , Mahmud Omar , Abdulla Watad , Tal Patalon , Mohammad E. Naffaa
Objective
The association between FMF and incident liver cirrhosis is not widely studied. In this study, we aimed to examine the association between FMF and incident liver cirrhosis in a population-based cohort.
Methods
Patients with FMF aged ≥ 18 in the Maccabi Healthcare Services (MHS) database were identified according to ICD-9 code 277.31 between January 1st, 2000 and December 31st, 2022. A control group was 1:1 age and gender-matched. Patients with chronic liver disease or cirrhosis were excluded, as well as patients who were treated with methotrexate, amiodarone or tamoxifen and patients with less than 12 months of follow-up. Incident cirrhosis was defined as a new diagnosis of cirrhosis according to ICD-9 code (571.5), newly diagnosed major cirrhotic complications or liver transplantation. The Cox proportional hazards models were used to examine the association between FMF and incident cirrhosis and the Kaplan-Meier curves to study the event-free survival.
Results
Incident cirrhosis was detected among 2.1% and 0.4% in the study and control groups, respectively, P < 0.01. Being in the FMF group was associated with a significantly increased risk of incident cirrhosis (HR = 2.60, 95% CI: 1.54–4.38, P < 0.01). At 7 years, the cirrhosis-free survival rate was 98.2% in the study group and 99.6% in the control group (P < 0.01).
Conclusion
FMF was associated with incident cirrhosis, irrespective of the traditional risk factors for metabolic syndrome, suggesting the contribution of the inflammatory state to the development of cirrhosis.
{"title":"The association between familial Mediterranean fever and incident cirrhosis: A population-based matched cohort study","authors":"Michal Carmiel-Haggai , Rula Daood , Fadi Fassan , Helana Jeries , Dikla Dror-Zur , Mahmud Omar , Abdulla Watad , Tal Patalon , Mohammad E. Naffaa","doi":"10.1016/j.jbspin.2025.105917","DOIUrl":"10.1016/j.jbspin.2025.105917","url":null,"abstract":"<div><h3>Objective</h3><div>The association between FMF and incident liver cirrhosis is not widely studied. In this study, we aimed to examine the association between FMF and incident liver cirrhosis in a population-based cohort.</div></div><div><h3>Methods</h3><div>Patients with FMF aged<!--> <!-->≥<!--> <!-->18 in the Maccabi Healthcare Services (MHS) database were identified according to ICD-9 code 277.31 between January 1st, 2000 and December 31st, 2022. A control group was 1:1 age and gender-matched. Patients with chronic liver disease or cirrhosis were excluded, as well as patients who were treated with methotrexate, amiodarone or tamoxifen and patients with less than 12 months of follow-up. Incident cirrhosis was defined as a new diagnosis of cirrhosis according to ICD-9 code (571.5), newly diagnosed major cirrhotic complications or liver transplantation. The Cox proportional hazards models were used to examine the association between FMF and incident cirrhosis and the Kaplan-Meier curves to study the event-free survival.</div></div><div><h3>Results</h3><div>Incident cirrhosis was detected among 2.1% and 0.4% in the study and control groups, respectively, <em>P</em> <!--><<!--> <!-->0.01. Being in the FMF group was associated with a significantly increased risk of incident cirrhosis (HR<!--> <!-->=<!--> <!-->2.60, 95% CI: 1.54–4.38, <em>P</em> <!--><<!--> <!-->0.01). At 7 years, the cirrhosis-free survival rate was 98.2% in the study group and 99.6% in the control group (<em>P</em> <!--><<!--> <!-->0.01).</div></div><div><h3>Conclusion</h3><div>FMF was associated with incident cirrhosis, irrespective of the traditional risk factors for metabolic syndrome, suggesting the contribution of the inflammatory state to the development of cirrhosis.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105917"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-04-30DOI: 10.1016/j.jbspin.2025.105916
Julio Ramírez , Vicenç Torrente-Segarra , Andrea Cuervo , Mireia Moreno , Ana Belén Azuaga , Lourdes Mateo , Beatriz Frade-Sosa , Andrea Zacarías , Noemí Busquets-Pérez , Susana Holgado , Paula Estrada , Oscar Camacho , Juan José De Agustín , Carme Moragues , María Bonet , Sandra Farietta , Patricia Corzo , Andrés Ponce , Virginia Ruiz-Esquide , Lucía Alascio , Juan D. Cañete
Objectives
To define ultrasound (US) characteristics in patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) exhibiting active hand inflammation.
Methods
This cross-sectional, multicenter study collected epidemiological and clinical data from RA and PsA patients with active hand inflammation. US examinations of wrists and metacarpophalangeal joints were performed, focusing on extensor and flexor tendons.
Results
A total of 292 patients were included: 192 (61.7%) were women, with a mean age of 56.1 years and mean disease duration of 105.4 months. Ninety-one patients (31.1%) had seropositive RA, 79 (27%) had seronegative RA, and 122 (41.7%) had PsA. Overall, 125 patients (42.8%) exhibited erosive disease, with 103 (35.2%) receiving targeted therapies. All patients had active disease (mean SDAI: 29.5; mean DAPSA: 22.3). Among the cohort, 144 patients (49.3%) showed synovial hypertrophy (SH) ≥ 2 + Power Doppler (PD). This was more common in seropositive (72.5%) than in seronegative RA (43%) or PsA (36%) (P ≤ 0.001). Erosive disease (OR 8.4 [3.9–18], P ≤ 0.001) and US global score (OR 1.1 [1–1.1], P ≤ 0.001) were associated with SH ≥ 2 + PD. Extensor paratenonitis was more frequent in PsA (27%) compared to seropositive (9.8%) and seronegative RA (18.9%) (P ≤ 0.01). The number of swollen joints (OR 1.1 [1–1.2], P ≤ 0.001) and joint ankylosis (OR 4.3 [1.1–16.9], P ≤ 0.05) were positively associated with paratenonitis.
Conclusions
Synovial pannus was characteristic of RA, while paratenonitis was more common in PsA. SH ≥ 2 + PD correlated with erosive disease, highlighting the need for prospective studies to validate US as a decision-making tool in arthritis.
{"title":"Active hand inflammation. Differing clinical and ultrasound patterns in patients with rheumatoid arthritis and psoriatic arthritis – A cross-sectional, multicenter study","authors":"Julio Ramírez , Vicenç Torrente-Segarra , Andrea Cuervo , Mireia Moreno , Ana Belén Azuaga , Lourdes Mateo , Beatriz Frade-Sosa , Andrea Zacarías , Noemí Busquets-Pérez , Susana Holgado , Paula Estrada , Oscar Camacho , Juan José De Agustín , Carme Moragues , María Bonet , Sandra Farietta , Patricia Corzo , Andrés Ponce , Virginia Ruiz-Esquide , Lucía Alascio , Juan D. Cañete","doi":"10.1016/j.jbspin.2025.105916","DOIUrl":"10.1016/j.jbspin.2025.105916","url":null,"abstract":"<div><h3>Objectives</h3><div>To define ultrasound (US) characteristics in patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) exhibiting active hand inflammation.</div></div><div><h3>Methods</h3><div>This cross-sectional, multicenter study collected epidemiological and clinical data from RA and PsA patients with active hand inflammation. US examinations of wrists and metacarpophalangeal joints were performed, focusing on extensor and flexor tendons.</div></div><div><h3>Results</h3><div>A total of 292 patients were included: 192 (61.7%) were women, with a mean age of 56.1 years and mean disease duration of 105.4 months. Ninety-one patients (31.1%) had seropositive RA, 79 (27%) had seronegative RA, and 122 (41.7%) had PsA. Overall, 125 patients (42.8%) exhibited erosive disease, with 103 (35.2%) receiving targeted therapies. All patients had active disease (mean SDAI: 29.5; mean DAPSA: 22.3). Among the cohort, 144 patients (49.3%) showed synovial hypertrophy (SH)<!--> <!-->≥<!--> <!-->2<!--> <!-->+<!--> <!-->Power Doppler (PD). This was more common in seropositive (72.5%) than in seronegative RA (43%) or PsA (36%) (<em>P</em> <!-->≤<!--> <!-->0.001). Erosive disease (OR 8.4 [3.9–18], <em>P</em> <!-->≤<!--> <!-->0.001) and US global score (OR 1.1 [1–1.1], <em>P</em> <!-->≤<!--> <!-->0.001) were associated with SH<!--> <!-->≥<!--> <!-->2<!--> <!-->+<!--> <!-->PD. Extensor paratenonitis was more frequent in PsA (27%) compared to seropositive (9.8%) and seronegative RA (18.9%) (<em>P</em> <!-->≤<!--> <!-->0.01). The number of swollen joints (OR 1.1 [1–1.2], <em>P</em> <!-->≤<!--> <!-->0.001) and joint ankylosis (OR 4.3 [1.1–16.9], <em>P</em> <!-->≤<!--> <!-->0.05) were positively associated with paratenonitis.</div></div><div><h3>Conclusions</h3><div>Synovial pannus was characteristic of RA, while paratenonitis was more common in PsA. SH<!--> <!-->≥<!--> <!-->2<!--> <!-->+<!--> <!-->PD correlated with erosive disease, highlighting the need for prospective studies to validate US as a decision-making tool in arthritis.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105916"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-08-28DOI: 10.1016/j.jbspin.2025.105955
Saskia P.M. Truijen , Annelies Boonen , Carla J.H. van der Kallen , Annemarie Koster , Hans Bosma , Marloes van Onna
Objective
To test the hypothesis that older age negatively impacts the association between chronic musculoskeletal pain (MSP) and health-related quality of life (HRQoL).
Methods
Cross-sectional data of 8618 participants aged 40–75 years from the population-based Maastricht Study cohort was used. Chronic MSP presence was self-reported. Pain intensity was measured on a 0–10 scale (10: unbearable pain). Age (seven groups) and chronic MSP (intensity) were regressed in multivariable analyses on (components of) HRQoL: the mental (MCS) and physical component score (PCS) of the 36-item Short Form Survey (SF-36), the EuroQol-VAS measuring overall HRQoL, and (un)paid work days lost in the past six months. Interactions between age groups and chronic MSP were examined.
Results
Chronic MSP was reported by 2513/8618 (29%) participants and was associated with worse PCS (β = −7.4, 95%CI: −7.8 to −7.1), MCS (β = −1.8, 95%CI: −2.2 to −1.5), EuroQol-VAS (β = −7.9, 95%CI: −8.9 to −7.0), and a higher likelihood of unproductive days (OR = 2.1, 95%CI:1.9–2.4). An interaction between age group and MSP was only observed for mental health: The negative impact of MSP on mental health was lower in individuals aged 70–75 years (β = −0.4, 95%CI: −1.3 to 0.6) compared to those aged 40–44 years (β = −3.1, 95%CI: −5.0 to −1.2) (pinteraction < 0.05). Age > 60 years was associated with fewer unproductive days, independent of MSP (ORrange age groups: 0.6 to 0.3; all P < 0.01).
Conclusion
Although chronic MSP negatively affects physical and mental health as well as work productivity, our findings suggest an unexpected resilience in mental HRQoL among older adults.
{"title":"The impact of older age on the relation between chronic musculoskeletal pain and health-related quality of life: The Maastricht Study","authors":"Saskia P.M. Truijen , Annelies Boonen , Carla J.H. van der Kallen , Annemarie Koster , Hans Bosma , Marloes van Onna","doi":"10.1016/j.jbspin.2025.105955","DOIUrl":"10.1016/j.jbspin.2025.105955","url":null,"abstract":"<div><h3>Objective</h3><div>To test the hypothesis that older age negatively impacts the association between chronic musculoskeletal pain (MSP) and health-related quality of life (HRQoL).</div></div><div><h3>Methods</h3><div>Cross-sectional data of 8618 participants aged 40–75 years from the population-based Maastricht Study cohort was used. Chronic MSP presence was self-reported. Pain intensity was measured on a 0–10 scale (10: unbearable pain). Age (seven groups) and chronic MSP (intensity) were regressed in multivariable analyses on (components of) HRQoL: the mental (MCS) and physical component score (PCS) of the 36-item Short Form Survey (SF-36), the EuroQol-VAS measuring overall HRQoL, and (un)paid work days lost in the past six months. Interactions between age groups and chronic MSP were examined.</div></div><div><h3>Results</h3><div>Chronic MSP was reported by 2513/8618 (29%) participants and was associated with worse PCS (β<!--> <!-->=<!--> <!-->−7.4, 95%CI: −7.8 to −7.1), MCS (β<!--> <!-->=<!--> <!-->−1.8, 95%CI: −2.2 to −1.5), EuroQol-VAS (β<!--> <!-->=<!--> <!-->−7.9, 95%CI: −8.9 to −7.0), and a higher likelihood of unproductive days (OR<!--> <!-->=<!--> <!-->2.1, 95%CI:1.9–2.4). An interaction between age group and MSP was only observed for mental health: The negative impact of MSP on mental health was lower in individuals aged 70–75 years (β<!--> <!-->=<!--> <!-->−0.4, 95%CI: −1.3 to 0.6) compared to those aged 40–44 years (β<!--> <!-->=<!--> <!-->−3.1, 95%CI: −5.0 to −1.2) (<em>p</em><sub>interaction</sub> <!--><<!--> <!-->0.05). Age<!--> <!-->><!--> <!-->60 years was associated with fewer unproductive days, independent of MSP (OR<sub>range</sub> age groups: 0.6 to 0.3; all <em>P</em> <!--><<!--> <!-->0.01).</div></div><div><h3>Conclusion</h3><div>Although chronic MSP negatively affects physical and mental health as well as work productivity, our findings suggest an unexpected resilience in mental HRQoL among older adults.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105955"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-04-02DOI: 10.1016/j.jbspin.2025.105898
Florence A. Trémollieres, Anna Gosset
{"title":"Back to hormonal replacement therapy","authors":"Florence A. Trémollieres, Anna Gosset","doi":"10.1016/j.jbspin.2025.105898","DOIUrl":"10.1016/j.jbspin.2025.105898","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105898"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-04-29DOI: 10.1016/j.jbspin.2025.105910
Daniel Aletaha, Daniela Sieghart
{"title":"Rheumatoid arthritis before rheumatoid arthritis: What can we learn from clinical trials?","authors":"Daniel Aletaha, Daniela Sieghart","doi":"10.1016/j.jbspin.2025.105910","DOIUrl":"10.1016/j.jbspin.2025.105910","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105910"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-04-02DOI: 10.1016/j.jbspin.2025.105897
Tristan Pascart
{"title":"Imaging in the assessment of deposits in gout: From research to daily clinical implementation","authors":"Tristan Pascart","doi":"10.1016/j.jbspin.2025.105897","DOIUrl":"10.1016/j.jbspin.2025.105897","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105897"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-05-26DOI: 10.1016/j.jbspin.2025.105929
Yinglun Zhang , Zhibin Jin , Jing Yao , Dandan Wang , Yunxian Yu , Weijing Zhang
Objectives
To evaluate the trends and cross-country inequalities of gout burden in people aged 15–39 years from 1990 to 2021, with projections to 2035.
Methods
The study employed estimates from Global Burden of Diseases (GBD) 2021 to assess prevalence, incidence, and years lived with disability (YLDs) of gout across global, demographic, GBD regional, national, sociodemographic index (SDI) regional, and risk factor levels. Temporal trends in the age-standardized rates (ASRs) of prevalence, incidence and YLDs were assessed by Joinpoint regression, while associations between SDI and ASRs were examined through Spearman correlation. Health inequalities were measured using the slope index of inequality and the concentration index. Future trends were forecast by a Bayesian age-period-cohort model.
Results
The burden of gout increased in global, demographic, GBD regional, and SDI level from 1990 to 2021. Males, the 35–39 years subgroup, and High-SDI regions experienced the highest burden. High-income North America owned the highest ASRs while East Asia reported the largest numbers. A moderate positive correlation was observed between gout burden and SDI for nations. Both absolute and relative inequalities increased. Males had higher YLDs due to high body mass index (BMI), females due to kidney dysfunction. Although ASRs were predicted to decrease from 2020 to 2035, numbers were predicted to rise.
Conclusions
The gout burden gout in people aged 15–39 years increased with notable inequalities. Despite projected ASRs decreases, overall numbers were likely to increase, highlighting the urgent need for targeted interventions and public health strategies.
{"title":"Global, regional, and national burden of gout in people aged 15–39 years from 1990 to 2021: Trends, cross-country inequalities and forecast to 2035","authors":"Yinglun Zhang , Zhibin Jin , Jing Yao , Dandan Wang , Yunxian Yu , Weijing Zhang","doi":"10.1016/j.jbspin.2025.105929","DOIUrl":"10.1016/j.jbspin.2025.105929","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the trends and cross-country inequalities of gout burden in people aged 15–39 years from 1990 to 2021, with projections to 2035.</div></div><div><h3>Methods</h3><div>The study employed estimates from Global Burden of Diseases (GBD) 2021 to assess prevalence, incidence, and years lived with disability (YLDs) of gout across global, demographic, GBD regional, national, sociodemographic index (SDI) regional, and risk factor levels. Temporal trends in the age-standardized rates (ASRs) of prevalence, incidence and YLDs were assessed by Joinpoint regression, while associations between SDI and ASRs were examined through Spearman correlation. Health inequalities were measured using the slope index of inequality and the concentration index. Future trends were forecast by a Bayesian age-period-cohort model.</div></div><div><h3>Results</h3><div>The burden of gout increased in global, demographic, GBD regional, and SDI level from 1990 to 2021. Males, the 35–39 years subgroup, and High-SDI regions experienced the highest burden. High-income North America owned the highest ASRs while East Asia reported the largest numbers. A moderate positive correlation was observed between gout burden and SDI for nations. Both absolute and relative inequalities increased. Males had higher YLDs due to high body mass index (BMI), females due to kidney dysfunction. Although ASRs were predicted to decrease from 2020 to 2035, numbers were predicted to rise.</div></div><div><h3>Conclusions</h3><div>The gout burden gout in people aged 15–39 years increased with notable inequalities. Despite projected ASRs decreases, overall numbers were likely to increase, highlighting the urgent need for targeted interventions and public health strategies.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105929"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-06-24DOI: 10.1016/j.jbspin.2025.105934
Marco Di Battista , Chiara Romei , Laura Tavanti , Vincenzo Uggenti , Sara Mitolo , Edoardo Airò , Francesco Pistelli , Davide Chimera , Laura Carrozzi , Emanuele Neri , Annalisa De Liperi , Alessandra Della Rossa , Marta Mosca
Objective
We assessed the effect of nintedanib (NIN) in terms of quantitative HRCT changes in both idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated progressive interstitial lung disease (SSc-ILD), evaluating the relationships between imaging variations and clinical-functional outcomes.
Methods
We prospectively enrolled SSc-ILD and IPF patients treated with NIN and retrospectively selected the same number of subjects from a historical untreated cohort comparable for disease, age, gender and follow-up period. HRCT scans were processed with CALIPER software, obtaining the percentage of normal parenchyma, ILD and vascular-related structures (VRS).
Results
Quantitative HRCT changes of 36 NIN treated patients (12 SSc-ILD and 24 IPF) were compared with 36 untreated subjects with pulmonary fibrosis. After a mean follow-up period of 22 months, NIN therapy was associated with a percentage stabilization of normal parenchyma (from 81.3 ± 11.8% to 78.6 ± 15.6%; P = not significant) and ILD (from 14.5 ± 10.4% to 16.7 ± 14.2%; P = not significant) both in SSc-ILD and IPF, avoiding the loss of normal parenchyma (from 87.4 ± 7.3% to 78.8 ± 16.7%; P < 0.001) and ILD worsening (from 9.0 ± 5.9% to 16.5 ± 14.8%; P < 0.001) observed in the untreated cohort. VRS was significantly increased regardless of antifibrotic therapy (P < 0.001). NIN treated patients who experienced a clinically meaningful worsening at pulmonary function tests or at the reported dyspnoea, presented a significant loss of normal parenchyma in parallel with a greater increase in ILD (P < 0.05 for all).
Conclusion
NIN appears effective in reducing the radiological decline of pulmonary fibrosis. Quantitative HRCT is proposed as a surrogate outcome measure for clinical practice and future trials.
{"title":"Quantitative HRCT as a surrogate outcome measure for nintedanib treatment in systemic sclerosis-interstitial lung disease and idiopathic pulmonary fibrosis","authors":"Marco Di Battista , Chiara Romei , Laura Tavanti , Vincenzo Uggenti , Sara Mitolo , Edoardo Airò , Francesco Pistelli , Davide Chimera , Laura Carrozzi , Emanuele Neri , Annalisa De Liperi , Alessandra Della Rossa , Marta Mosca","doi":"10.1016/j.jbspin.2025.105934","DOIUrl":"10.1016/j.jbspin.2025.105934","url":null,"abstract":"<div><h3>Objective</h3><div>We assessed the effect of nintedanib (NIN) in terms of quantitative HRCT changes in both idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated progressive interstitial lung disease (SSc-ILD), evaluating the relationships between imaging variations and clinical-functional outcomes.</div></div><div><h3>Methods</h3><div>We prospectively enrolled SSc-ILD and IPF patients treated with NIN and retrospectively selected the same number of subjects from a historical untreated cohort comparable for disease, age, gender and follow-up period. HRCT scans were processed with CALIPER software, obtaining the percentage of normal parenchyma, ILD and vascular-related structures (VRS).</div></div><div><h3>Results</h3><div>Quantitative HRCT changes of 36 NIN treated patients (12 SSc-ILD and 24 IPF) were compared with 36 untreated subjects with pulmonary fibrosis. After a mean follow-up period of 22 months, NIN therapy was associated with a percentage stabilization of normal parenchyma (from 81.3<!--> <!-->±<!--> <!-->11.8% to 78.6<!--> <!-->±<!--> <!-->15.6%; <em>P</em> <!-->=<!--> <!-->not significant) and ILD (from 14.5<!--> <!-->±<!--> <!-->10.4% to 16.7<!--> <!-->±<!--> <!-->14.2%; <em>P</em> <!-->=<!--> <!-->not significant) both in SSc-ILD and IPF, avoiding the loss of normal parenchyma (from 87.4<!--> <!-->±<!--> <!-->7.3% to 78.8<!--> <!-->±<!--> <!-->16.7%; <em>P</em> <!--><<!--> <!-->0.001) and ILD worsening (from 9.0<!--> <!-->±<!--> <!-->5.9% to 16.5<!--> <!-->±<!--> <!-->14.8%; <em>P</em> <!--><<!--> <!-->0.001) observed in the untreated cohort. VRS was significantly increased regardless of antifibrotic therapy (<em>P</em> <!--><<!--> <!-->0.001). NIN treated patients who experienced a clinically meaningful worsening at pulmonary function tests or at the reported dyspnoea, presented a significant loss of normal parenchyma in parallel with a greater increase in ILD (<em>P</em> <!--><<!--> <!-->0.05 for all).</div></div><div><h3>Conclusion</h3><div>NIN appears effective in reducing the radiological decline of pulmonary fibrosis. Quantitative HRCT is proposed as a surrogate outcome measure for clinical practice and future trials.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105934"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gout and calcium pyrophosphate deposition disease (CPPD) are two highly prevalent causes of inflammatory arthritis, characterized by the pathological deposition of monosodium urate (MSU) and CPP crystals, respectively, in joint tissues. These crystals can induce an intense inflammatory response, known as crystal-induced inflammation, which involves innate immunity and is highly dependent of the activation of interleukin 1β (IL-1β) following the recruitment of the NLRP3 inflammasome. In patients in whom first-line treatments (colchicine, prednisone, NSAIDs) are either ineffective or inappropriate, IL-1 inhibitors can be used to treat acute crystal-induced arthritis. However, some patients do not respond to these therapies, or experience adverse events. There is therefore a need for other treatments, particularly in CPPD, where the inflammation induced by CPP crystals can be chronic and affect elderly patients, making IL-1 inhibitors a less suitable option. IL-6, which is highly expressed during crystal-induced inflammation, is emerging as a promising therapeutic target in chronic CPP arthritis, with publications reporting the efficacy of tocilizumab in patients with inadequate response to other treatments, including anakinra, the most commonly used IL-1 inhibitor in this indication (off-label). These data require confirmation in randomized controlled trials. Other therapies, such as JAK inhibitors or NLRP3 inhibitors, may also be of interest in crystal-induced arthritis.
{"title":"IL-6: A new target in crystal-induced arthritides – A narrative review","authors":"Augustin Latourte , Tristan Pascart , Pascal Richette","doi":"10.1016/j.jbspin.2025.105935","DOIUrl":"10.1016/j.jbspin.2025.105935","url":null,"abstract":"<div><div>Gout and calcium pyrophosphate deposition disease (CPPD) are two highly prevalent causes of inflammatory arthritis, characterized by the pathological deposition of monosodium urate (MSU) and CPP crystals, respectively, in joint tissues. These crystals can induce an intense inflammatory response, known as crystal-induced inflammation, which involves innate immunity and is highly dependent of the activation of interleukin 1β (IL-1β) following the recruitment of the NLRP3 inflammasome. In patients in whom first-line treatments (colchicine, prednisone, NSAIDs) are either ineffective or inappropriate, IL-1 inhibitors can be used to treat acute crystal-induced arthritis. However, some patients do not respond to these therapies, or experience adverse events. There is therefore a need for other treatments, particularly in CPPD, where the inflammation induced by CPP crystals can be chronic and affect elderly patients, making IL-1 inhibitors a less suitable option. IL-6, which is highly expressed during crystal-induced inflammation, is emerging as a promising therapeutic target in chronic CPP arthritis, with publications reporting the efficacy of tocilizumab in patients with inadequate response to other treatments, including anakinra, the most commonly used IL-1 inhibitor in this indication (off-label). These data require confirmation in randomized controlled trials. Other therapies, such as JAK inhibitors or NLRP3 inhibitors, may also be of interest in crystal-induced arthritis.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105935"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号